Phage therapy is an alternative approach to overcoming the problem of multidrug resistance in bacteria. In this study, we isolated and purified a virulent phage named vB_AhaP_PT2 from A. hydrophila-TPS. We examined the biological characteristics and genome sequences of vB_AhaP_PT2. After intraperitoneal injection of bacteriophage (8 × 107 PFU/mL) into crucian carp, most of the phage distributed in the liver, spleen, kidney, intestine, and peripheral blood, and disappeared within 72 h. No substantial adverse symptoms were found in major organs after receiving phage injections continuously for 14 days. Vitro and Vivo results indicated that phage can effectively eliminate A. hydrophila-TPS. The phage vB_AhaP_PT2 (8 × 107 PFU/mL, 100 μL) can effectively protect the fish that exhibited a double median lethal dose of bacteria (2 × 106 CFU/fish). Although phage vB_AhaP_PT2 triggered the generation of phage-specific antibodies in carp, when the antibody titer was maximum, 8 × 107 PFU doses of bacteriophage could still protect crucian carp with lethal bacterial infections, the survival rate could reach 80 %. We also found that members of the genus Aeromonas could enter and colonize the intestine. The phage vB_AhaP_PT2 reduced the number of colonies of the genus Aeromonas. However, no significant changes were observed in α-diversity and β-diversity parameters, which suggested that the consumed phage had little effect on the intestine microflora. All the above results suggested that vB_AhaP_PT2 was a safe and effective therapeutic that can be considered as a potential tool to treat the infection caused by A. hydrophila-TPS in aquaculture.
Read full abstract